What 10 Analyst Ratings Have To Say About Best Buy Co

Best Buy Co (NYSE:BBY) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent…

Best Buy Co (NYSE:BBY) has observed the following analyst ratings within the last quarter:

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 1 0 7 0 2
Last 30D 0 0 0 0 1
1M Ago 0 0 0 0 0
2M Ago 0 0 0 0 0
3M Ago 1 0 7 0 1

According to 10 analyst offering 12-month price targets in the last 3 months, Best Buy Co has an average price target of $75.2 with a high of $87.00 and a low of $62.00.

Below is a summary of how these 10 analysts rated Best Buy Co over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock

price target chart

This current average has decreased by 7.16% from the previous average price target of $81.00.

Stay up to date on Best Buy Co analyst ratings.

What Are Analyst Ratings?

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Infection-Focused Barinthus Bio’s VTP-200 Data Underwhelming: Analyst Weighs On Mixed Perspectives

Explore the latest findings from Barinthus Biotherapeutics on VTP-200's performance in the APOLLO trial for low-grade cervical lesions linked to persistent hrHPV infection. Positive trends were noted, though not statistically significant. No major safety concerns were observed.

BRNS